Objective: The aim of this study was to investigate everolimus efficacy in well-moderately differentiated pancreatic NEC (pNEC) G3. Methods: This was a retrospective analysis of patients with pNEC G3 and Ki67 20% to 55% treated with everolimus. Results: Fifteen patients with median Ki67 30%and Eastern Cooperative Oncology Group performance status 0 to 1 were evaluated. Of these, 4 patients received everolimus as first-line treatment, whereas 11 had been pretreated with chemotherapy or peptide receptor radionuclide therapy. Median progression-free survival was 6 months, and median overall survival was 28 months. Eleven patients achieved disease stabilization (DS) at 3 month follow-up. Six patients (40%) maintained DS for at least 12 months. Three of 4 patients who received everolimus as first-line therapy had sustained DS (progression-free survival, 12, 17, and 22 months). The safety profile was consistent with that previously reported, with adverse events occurring in 9 patients (66.7%). Conclusions: This study suggests that everolimus is active in pNECG3with well-moderately differentiated morphology andKi67 less than 55%, inwhich more toxic systemic chemotherapy is, to date, the only available treatment.
Panzuto, F., Rinzivillo, M., Spada, F., Antonuzzo, L., Ibrahim, T., Campana, D., et al. (2017). Everolimus in pancreatic neuroendocrine carcinomas G3. PANCREAS, 46(3), 302-305 [10.1097/MPA.0000000000000762].
Everolimus in pancreatic neuroendocrine carcinomas G3
CAMPANA, DAVIDE;
2017
Abstract
Objective: The aim of this study was to investigate everolimus efficacy in well-moderately differentiated pancreatic NEC (pNEC) G3. Methods: This was a retrospective analysis of patients with pNEC G3 and Ki67 20% to 55% treated with everolimus. Results: Fifteen patients with median Ki67 30%and Eastern Cooperative Oncology Group performance status 0 to 1 were evaluated. Of these, 4 patients received everolimus as first-line treatment, whereas 11 had been pretreated with chemotherapy or peptide receptor radionuclide therapy. Median progression-free survival was 6 months, and median overall survival was 28 months. Eleven patients achieved disease stabilization (DS) at 3 month follow-up. Six patients (40%) maintained DS for at least 12 months. Three of 4 patients who received everolimus as first-line therapy had sustained DS (progression-free survival, 12, 17, and 22 months). The safety profile was consistent with that previously reported, with adverse events occurring in 9 patients (66.7%). Conclusions: This study suggests that everolimus is active in pNECG3with well-moderately differentiated morphology andKi67 less than 55%, inwhich more toxic systemic chemotherapy is, to date, the only available treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.